Brain Cancer Canada Awards an $80,000 research grant to the development of dual function therapies that harness the body's own immune system to kill brain tumour cells in glioblastomas TORONTO, May 23, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada is excited to announce $80,000 research grant has been awarded to Dr. Peter Stirling, PhD, Associate Professor at the University of...

TB Immunotherapy Collaboration Agreement With Stirling Products and Zodiac Capital Agreement to fast-track introduction of new Immunoxel/Dzherelo tablet as adjunct immunotherapy, especially for MDR-TB VANCOUVER, British Columbia, May 30, 2011 (GLOBE NEWSWIRE) -- Immune...